Target type: cellularcomponent
A protein complex that binds macrophage migration inhibitory factor. Comprises CD74 and CD44 cell surface proteins. [GOC:BHF, PMID:12782713, PMID:17045821]
The macrophage migration inhibitory factor (MIF) receptor complex is a multimeric assembly of proteins located on the cell surface that plays a crucial role in mediating the biological effects of MIF, a pleiotropic cytokine with diverse functions in inflammation, immunity, and metabolism. The core components of the complex are the MIF receptor (CD74), a type II transmembrane protein that binds MIF with high affinity, and CD44, a cell adhesion molecule involved in cell signaling and migration. While the exact stoichiometry and composition of the complex are still under investigation, studies have revealed that the interaction of MIF with CD74 triggers the recruitment of other proteins, including CD44, to form a signaling platform on the cell surface. The MIF receptor complex functions as a signal transduction hub, activating downstream pathways involved in cell survival, proliferation, inflammation, and immune responses. The binding of MIF to CD74 initiates a cascade of events that involve the activation of intracellular signaling molecules, such as Src kinases, MAPKs, and NF-κB, leading to the transcription of target genes involved in various cellular processes. The MIF receptor complex also interacts with other signaling molecules, including integrins, toll-like receptors, and chemokine receptors, further amplifying the effects of MIF and contributing to its diverse biological actions. Notably, the formation and function of the MIF receptor complex can be modulated by other factors, including post-translational modifications of CD74, the presence of other ligands for CD74, and the cellular context. This complexity highlights the dynamic nature of the MIF receptor complex and its critical role in regulating cellular responses to MIF.'
"
| Protein | Definition | Taxonomy |
|---|---|---|
| CD44 antigen | A CD44 molecule that is encoded in the genome of human. [PRO:WCB, UniProtKB:P16070] | Homo sapiens (human) |
| HLA class II histocompatibility antigen gamma chain | An MHC class II histocompatibility antigen gamma chain that is encoded in the genome of human. [PRO:WCB, UniProtKB:P04233] | Homo sapiens (human) |
| Compound | Definition | Classes | Roles |
|---|---|---|---|
| 1,2,3,4-tetrahydroisoquinoline | 1,2,3,4-tetrahydroisoquinoline: RN given refers to cpd with locants as specified | isoquinolines | |
| crizotinib | crizotinib : A 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that has R configuration at the chiral centre. The active enantiomer, it acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) Crizotinib: A piperidine and aminopyridine derivative that acts as an inhibitor of RECEPTOR PROTEIN-TYROSINE KINASES, including ANAPLASTIC LYMPHOMA KINASE (ALK) and HEPATOCYTE GROWTH FACTOR RECEPTOR (HGFR; c-Met). It is used in the treatment of NON-SMALL CELL LUNG CANCER. | 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine | antineoplastic agent; biomarker; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor |
| pf-06463922 | lorlatinib : A cyclic ether that is 16,17-dihydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecin-15(10H)-one substituted by methyl groups at positions 2 and 10R, and by cyano, amino and fluoro groups at positions 3, 7 and 12 respectively. It is a small molecule inhibitor of ALK and ROS1 kinase developed by Pfizer for the treatment of ALK-positive non-small cell lung cancer. lorlatinib: inhibits both anaplastic lymphoma kinase and c-ros oncogene 1 (ROS1) protein | aminopyridine; aromatic ether; azamacrocycle; benzamides; cyclic ether; monofluorobenzenes; nitrile; organic heterotetracyclic compound; pyrazoles | antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor |